Venture Life Group (LON:VLG) Shares Pass Above 50-Day Moving Average - Here's Why

Key Points

• Venture Life Group's stock price has crossed above its fifty-day moving average, trading at GBX 64.50 ($0.86) with a significant trading volume of 754,665 shares.
• The company reported a quarterly earnings per share (EPS) of GBX 3.96 ($0.05) and is expected to post an annual EPS of approximately 6.14.
• Insider Jerry Randall purchased 50,000 shares at GBX 59 ($0.78), indicating confidence in the company's performance as insiders currently hold 10.41% of the stock.

Venture Life Group plc (LON:VLG - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 55.30 ($0.74) and traded as high as GBX 66 ($0.89). Venture Life Group shares last traded at GBX 64.50 ($0.87), with a volume of 754,665 shares changing hands.

Venture Life Group Stock Performance

The company has a market capitalization of £83.46 million, a PE ratio of 111.15, a PEG ratio of 5.67 and a beta of 0.30. The company has a debt-to-equity ratio of 28.45, a quick ratio of 1.48 and a current ratio of 2.22. The company has a 50 day moving average price of GBX 55.96 and a 200 day moving average price of GBX 46.33.

Venture Life Group (LON:VLG - Get Free Report) last released its earnings results on Monday, June 30th. The company reported GBX 3.96 ($0.05) EPS for the quarter. Venture Life Group had a return on equity of 0.99% and a net margin of 1.44%. Equities analysts forecast that Venture Life Group plc will post 6.1391542 EPS for the current year.

Insider Activity

In other news, insider Jerry Randall purchased 50,000 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The shares were acquired at an average cost of GBX 59 ($0.79) per share, with a total value of £29,500 ($39,677.20). Corporate insiders own 10.41% of the company's stock.

About Venture Life Group

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples.